Moderna, Inc. 10-Q Summary: Q3 2025
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Moderna, Inc. is a biotechnology company developing mRNA medicines across four franchises: respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics, and rare disease therapeutics. The company currently commercializes three products: Spikevax (COVID-19), mRESVIA (RSV), and mNEXSPIKE (COVID-19, launched commercially in Q3 2025).
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $1,016 | $1,862 | $1,266 | $2,270 |
| Net Product Sales | $973 | $1,820 | $1,172 | $2,171 |
| Net (Loss) Income | $(200) | $13 | $(1,996) | $(2,441) |
| Diluted EPS | $(0.51) | $0.03 | $(5.15) | $(6.37) |
| Operating Cash Flow (9M) | $(2,803) | $(3,829) | — | — |
| Cash & Investments (Total) | $6,647 | — | — | — |
| Working Capital | $4,917 | — | — | — |
Note: Cash and investments decreased by $2.9 billion from year-end 2024 to $6.647 billion as of September 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 45% year-over-year in Q3 2025, driven primarily by a 47% drop in net product sales. This was attributed to lower COVID vaccination rates in the U.S. and international markets, the completion of advance purchase agreements, and the absence of a $140 million positive sales provision adjustment recorded in Q3 2024.
- Cost Reductions: Cost of sales decreased 60% in Q3 2025 due to lower inventory write-downs ($67 million vs. $214 million in Q3 2024) and reduced unutilized manufacturing capacity. R&D expenses fell 30% due to trial wind-downs and funding from the Blackstone arrangement.
- Profitability: The company returned to a net loss of $200 million in Q3 2025, compared to a net income of $13 million in Q3 2024. However, the nine-month net loss improved by 18% compared to the prior year.
- Inventory: Inventory levels increased to $332 million (from $117 million at year-end 2024) due to manufacturing of COVID vaccines, though write-downs were significantly lower than the prior year.
Guidance, Outlook, and Risks
- Outlook: Management anticipates a decline in full-year 2025 net product sales compared to 2024 due to lower vaccination rates and a more competitive market. Demand for COVID and RSV vaccines is expected to remain seasonal.
- Pipeline Updates:
- CMV Vaccine: The Phase 3 trial for mRNA-1647 failed to meet its primary efficacy endpoint; the congenital CMV program will be discontinued.
- Flu Vaccine: Phase 3 data for mRNA-1010 was presented; submissions for approval are expected by January 2026.
- Oncology: Progress continues on intismeran autogene (INT) with Merck, with multiple Phase 3 studies enrolling or fully enrolled.
- Liquidity: The company believes its cash, cash equivalents, and investments ($6.6 billion) are sufficient to fund operations for at least the next 12 months.
- Risks: Significant risks include ongoing patent litigation (e.g., against Pfizer/BioNTech, Arbutus, GSK), the transition of COVID vaccines to a seasonal commercial model, and the uncertainty of pipeline development timelines.
Key Facts for Investor Verification
- Revenue Sustainability: Verify the trajectory of COVID vaccine sales as the market shifts from government contracts to commercial/seasonal demand.
- CMV Program Discontinuation: Assess the impact of the failed CMV Phase 3 trial on the overall R&D portfolio and future cash burn.
- Inventory Valuation: Monitor inventory levels and potential future write-downs given the shelf-life constraints of mRNA vaccines (9-18 months).
- Legal Exposure: Track the status of ongoing patent infringement lawsuits, particularly those involving mRNA platform technology and lipid nanoparticles.
- Manufacturing Capacity: Evaluate the utilization rates of new international manufacturing facilities (Australia, UK, Canada) and their impact on cost of sales.